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YClopidogrel is a prodrug that requires activation by CYP2C19 and other isoenzymes of
the cytochrome P450 system. Carriers of a loss-of-function CYP2C19 allele have lower
levels of the active metabolite, resulting in reduced platelet inhibition and a potentially
higher rate of adverse cardiovascular events. As PPI are competitive inhibitors of
CYP2C19, coadministration with Clopidogrel can further reduce the latter’s antiplatelet
activity.
The COGENT randomised trial which enrolled predominantly white Caucasian
males did not demonstrate any adverse interaction between Clopidogrel and Omep-
razole use. However, this interaction may be signiﬁcant in Asian patients as up to 55%
of Asians carry a loss-of-function CYP2C19 allele as compared to 30% of Caucasians.
We hypothesize that Asian patients taking both Clopidogrel and the PPI Omeprazole
are at higher risk of adverse cardiovascular events post-PCI.
Methods: This retrospective cohort study in a 1300-bed tertiary hospital in Singapore
included all patients from 1st January to 31st December 2011 who had PCI and
received either Omeprazole or a H2RA, together with 12 months of Aspirin and
Clopidogrel. Prescription and outcome data were retrieved from electronic medical
records. The primary outcome was the incidence of cardiovascular complications
within 12 months of the initial PCI. Cardiovascular complication is deﬁned as car-
diovascular death, non-fatal myocardial infarction, need for urgent target vessel
revascularisation and ischemic stroke.
Results: We identiﬁed 933 patients, of which 614 patients met the criteria for in-
clusion. The primary outcome occurred in 27 of 296 patients (9.1%) from the
Omeprazole group and 13 of 318 patients (4.1%) from the H2RA group (p ¼ 0.014).
The difference remained statistically signiﬁcant after adjustment for baseline differ-
ences in cardiovascular risk factors in both groups (p ¼ 0.042).
Conclusions: Using Omeprazole rather than a H2RA was associated with a signif-
icantly greater incidence of cardiovascular complications in Asian patients on Clopi-
dogrel after PCI. Larger studies are required to further evaluate this observation.
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Background: The use of metformin in patients with non-insulin-dependent diabetes
mellitus (NIDDM) has been associated with improved cardiovascular outcomes. How-
ever, recent studies raise concern that use of metformin may inhibit endothelialization
following limus-eluting stent (LES) placement and increase the risk of stent thrombosis.
Therefore, we set out to study the impact of metformin on stent thrombosis and major
adverse cardiovascular events in patients that received drug-eluting stents (DES).
Methods: We evaluated consecutive patient with NIDDM discharged on oral anti-
hyperglycemic agents that underwent DES placement at our institution from 2003
through 2012. We assessed stent thrombosis, major adverse cardiovascular events
(MACE), target lesion revascularization, myocardial infarction, and all-cause mortality
at one year and analyzed the impact of metformin use and stent type on these outcomes.
Results: We included 1,201 patients with a mean age of 66  10 years, 64.1% were
male, 63.5% had ACS, 74.8% received LES, 25.2% received paclitaxel-eluting stents
(PES), and 55% were taking Metformin. There was no difference in stent thrombosis,
regardless of stent type or metformin use. Whether or not patients received LES or PES
did not signiﬁcantly impact MACE (Figure 1A) or all-cause mortality (Figure 1B).
Patients takingmetformin had a signiﬁcant reduction inMACE (p¼0.002) and all-cause
mortality (p¼0.002) compared with patients not taking metformin (Figure 1C and
Figure 1D, respectively). However, multivariate analysis demonstrated that stent type and
metformin use were not signiﬁcantly associated with MACE or all-cause mortality.
Conclusion: In patients with NIDDM, the use of metformin following placement of
DES did not increase the risk of stent thrombosis and MACE, regardless of the type
of stent placed.Chronic Total Occlusion
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Background: The presence of a chronic total occlusion (CTO) in up to 30% of
routine angiograms emphasizes the importance to select an optimal treatment strategy
effectiveness of its treatment and its implication in future clinical events.
Objective:We assessed the rationale for decision-making in treatment of CTO at our
institution.
Methods: From June 2010 to December 2012 we evaluated all consecutive patients in
our catheterization laboratory in which at least one CTO was diagnosed. Data were
prospectively collected on treatment decisions (medical vs. surgery vs. percutaneous
coronary intervention <PCI>), PCI indications and subsequent cardiac events
through time.
Results: 711 patients with at least one CTO in the basal coronary angiogram were
included. Two groups were made according to programmed to PCI (PPCI)¼189
patients and non-programed to PCI (NPPCI)¼522 patients. There was a statistical
difference among basal characteristics in patients PPCI vs. NPPCI with less acute
myocardial infarction (AMI) 16(13,6%) vs. 81(15,5%) p¼0.016; less involvement of
3-vessel disease 56(29,6%) vs. 224 (42,9%) p¼0.002; and less presence of coronary
left-main disease 12 (6,4%) vs. 72 (13,8%) p¼0.007. There was also a difference
between age (62,610.4 years vs. 68,310.7 years; p¼<0.0001); ejection fraction
(EF) (47,113,8% vs. 44,913,9;p¼0.017%) and creatinine clearance (70,8 28,6
ml/min vs. 62 23,1, ml/min; p¼<0.001). The multivariate analysis demonstrated
that the following variables in predicting no PCI as ﬁrst step approach in CTO
lesions: AMI, number of diseased vessels, left main lesion and age. There was a
trend to be treated by PCI as ﬁrst step approach in patients with positive ischemia
by a stress test.
Conclusion: In a large all comer CTO lesion population, in a University hospital; the
ﬁrst step approach of revascularization is dictated by clinical factors as age, comorbidity
(EF and creatinine clearance), AMI; anatomical factors such as left-main disease and
3-vessel disease. On the other hand, at our institution the choice of PCI as ﬁrst step
